|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KRT16 |
Gene summary for KRT16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KRT16 | Gene ID | 3868 |
| Gene name | keratin 16 | |
| Gene Alias | CK16 | |
| Cytomap | 17q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | P08779 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3868 | KRT16 | GSM4909285 | Human | Breast | IDC | 3.85e-11 | 5.40e-01 | 0.21 |
| 3868 | KRT16 | GSM4909286 | Human | Breast | IDC | 3.23e-06 | -2.45e-01 | 0.1081 |
| 3868 | KRT16 | GSM4909290 | Human | Breast | IDC | 1.82e-05 | -2.68e-01 | 0.2096 |
| 3868 | KRT16 | GSM4909291 | Human | Breast | IDC | 1.32e-04 | -2.73e-01 | 0.1753 |
| 3868 | KRT16 | GSM4909293 | Human | Breast | IDC | 1.22e-03 | -2.50e-01 | 0.1581 |
| 3868 | KRT16 | GSM4909294 | Human | Breast | IDC | 1.39e-04 | -2.59e-01 | 0.2022 |
| 3868 | KRT16 | GSM4909295 | Human | Breast | IDC | 6.48e-13 | 8.82e-01 | 0.0898 |
| 3868 | KRT16 | GSM4909296 | Human | Breast | IDC | 1.05e-06 | -2.63e-01 | 0.1524 |
| 3868 | KRT16 | GSM4909297 | Human | Breast | IDC | 1.01e-03 | -2.19e-01 | 0.1517 |
| 3868 | KRT16 | GSM4909298 | Human | Breast | IDC | 2.27e-06 | -2.72e-01 | 0.1551 |
| 3868 | KRT16 | GSM4909301 | Human | Breast | IDC | 1.75e-09 | -2.81e-01 | 0.1577 |
| 3868 | KRT16 | GSM4909302 | Human | Breast | IDC | 4.60e-07 | -2.38e-01 | 0.1545 |
| 3868 | KRT16 | GSM4909303 | Human | Breast | IDC | 2.16e-02 | -2.81e-01 | 0.0438 |
| 3868 | KRT16 | GSM4909304 | Human | Breast | IDC | 5.67e-08 | -2.79e-01 | 0.1636 |
| 3868 | KRT16 | GSM4909307 | Human | Breast | IDC | 1.00e-03 | -2.23e-01 | 0.1569 |
| 3868 | KRT16 | GSM4909308 | Human | Breast | IDC | 5.96e-11 | -2.81e-01 | 0.158 |
| 3868 | KRT16 | GSM4909311 | Human | Breast | IDC | 1.65e-06 | -2.39e-01 | 0.1534 |
| 3868 | KRT16 | GSM4909312 | Human | Breast | IDC | 1.60e-11 | -2.81e-01 | 0.1552 |
| 3868 | KRT16 | GSM4909319 | Human | Breast | IDC | 8.04e-10 | -2.77e-01 | 0.1563 |
| 3868 | KRT16 | GSM4909320 | Human | Breast | IDC | 3.28e-03 | -2.81e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00075688 | Breast | Precancer | aging | 41/1080 | 339/18723 | 5.95e-06 | 1.71e-04 | 41 |
| GO:00106319 | Breast | Precancer | epithelial cell migration | 40/1080 | 357/18723 | 4.57e-05 | 9.71e-04 | 40 |
| GO:00901329 | Breast | Precancer | epithelium migration | 40/1080 | 360/18723 | 5.51e-05 | 1.14e-03 | 40 |
| GO:00901309 | Breast | Precancer | tissue migration | 40/1080 | 365/18723 | 7.48e-05 | 1.47e-03 | 40 |
| GO:0045104 | Breast | Precancer | intermediate filament cytoskeleton organization | 11/1080 | 51/18723 | 1.26e-04 | 2.22e-03 | 11 |
| GO:0045103 | Breast | Precancer | intermediate filament-based process | 11/1080 | 52/18723 | 1.52e-04 | 2.60e-03 | 11 |
| GO:00508789 | Breast | Precancer | regulation of body fluid levels | 40/1080 | 379/18723 | 1.68e-04 | 2.77e-03 | 40 |
| GO:00016678 | Breast | Precancer | ameboidal-type cell migration | 47/1080 | 475/18723 | 2.19e-04 | 3.35e-03 | 47 |
| GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
| GO:00099136 | Breast | Precancer | epidermal cell differentiation | 23/1080 | 202/18723 | 1.43e-03 | 1.50e-02 | 23 |
| GO:00302163 | Breast | Precancer | keratinocyte differentiation | 17/1080 | 139/18723 | 2.71e-03 | 2.39e-02 | 17 |
| GO:000756813 | Breast | IDC | aging | 52/1434 | 339/18723 | 1.14e-06 | 5.10e-05 | 52 |
| GO:000166714 | Breast | IDC | ameboidal-type cell migration | 64/1434 | 475/18723 | 6.65e-06 | 2.05e-04 | 64 |
| GO:001063112 | Breast | IDC | epithelial cell migration | 51/1434 | 357/18723 | 1.14e-05 | 3.08e-04 | 51 |
| GO:009013212 | Breast | IDC | epithelium migration | 51/1434 | 360/18723 | 1.44e-05 | 3.70e-04 | 51 |
| GO:009013012 | Breast | IDC | tissue migration | 51/1434 | 365/18723 | 2.11e-05 | 5.11e-04 | 51 |
| GO:005087813 | Breast | IDC | regulation of body fluid levels | 50/1434 | 379/18723 | 1.12e-04 | 2.10e-03 | 50 |
| GO:00512712 | Breast | IDC | negative regulation of cellular component movement | 48/1434 | 367/18723 | 1.88e-04 | 3.12e-03 | 48 |
| GO:20001462 | Breast | IDC | negative regulation of cell motility | 46/1434 | 359/18723 | 4.01e-04 | 5.60e-03 | 46 |
| GO:00303362 | Breast | IDC | negative regulation of cell migration | 43/1434 | 344/18723 | 1.01e-03 | 1.13e-02 | 43 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
| hsa0491519 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
| hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
| hsa0491533 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
| hsa0491542 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
| hsa05150 | Breast | DCIS | Staphylococcus aureus infection | 19/846 | 96/8465 | 2.68e-03 | 1.67e-02 | 1.23e-02 | 19 |
| hsa0491552 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
| hsa051501 | Breast | DCIS | Staphylococcus aureus infection | 19/846 | 96/8465 | 2.68e-03 | 1.67e-02 | 1.23e-02 | 19 |
| hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
| hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
| hsa051504 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
| hsa0491524 | Cervix | HSIL_HPV | Estrogen signaling pathway | 19/459 | 138/8465 | 1.54e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa0515011 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
| hsa0491534 | Cervix | HSIL_HPV | Estrogen signaling pathway | 19/459 | 138/8465 | 1.54e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa0491529 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
| hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
| hsa04915210 | Oral cavity | NEOLP | Estrogen signaling pathway | 29/1112 | 138/8465 | 6.33e-03 | 2.34e-02 | 1.47e-02 | 29 |
| hsa0491537 | Oral cavity | NEOLP | Estrogen signaling pathway | 29/1112 | 138/8465 | 6.33e-03 | 2.34e-02 | 1.47e-02 | 29 |
| hsa0491527 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
| hsa04915112 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KRT16 | SNV | Missense_Mutation | novel | c.494N>A | p.Ser165Asn | p.S165N | P08779 | protein_coding | deleterious(0.02) | benign(0.192) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
| KRT16 | insertion | Frame_Shift_Ins | novel | c.1067_1068insTGTTGGT | p.Leu357ValfsTer38 | p.L357Vfs*38 | P08779 | protein_coding | TCGA-VQ-A925-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | ||
| KRT16 | insertion | Nonsense_Mutation | novel | c.1066_1067insTTGTTGCCTATTAAAGG | p.Ser356PhefsTer5 | p.S356Ffs*5 | P08779 | protein_coding | TCGA-VQ-A925-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |